کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2405256 1103027 2009 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine
چکیده انگلیسی

Since the introduction to the Swiss market in 1997, Crucell (former Berna Biotech Ltd.), has sold over 41 million doses worldwide of the virosomal adjuvanted influenza vaccine, Inflexal® V. Since 1992, 29 company sponsored clinical studies investigating the efficacy and safety of Inflexal® V have been completed in which 3920 subjects participated. During its decade on the market, Inflexal® V has shown an excellent tolerability profile due to its biocompatibility and purity. The vaccine contains no thiomersal or formaldehyde and its purity is reflected in the low ovalbumin content. By mimicking natural infection, the vaccine is highly efficacious. Inflexal® V is the only adjuvanted influenza vaccine licensed for all age groups and shows a good immunogenicity in both healthy and immunocompromised elderly, adults and children. This review presents and discusses the experience with Inflexal® V during the past decade.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 27, Issue 33, 16 July 2009, Pages 4381–4387
نویسندگان
, , , , , , ,